Investor Relations

MiNK Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel, first-in-class invariant natural killer T (iNKT) cell therapies to transform the lives of patients with cancer.
Press Releases
Apr 30, 2024
MiNK to Provide Corporate Update and First Quarter 2024 Financial Report
NEW YORK , April 30, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other
Mar 21, 2024
MiNK Reports Fourth Quarter and Year-End 2023 Results
Launched and enrolling Phase 2 trial of allo-iNKTs with botensilimab/balstilimab and chemotherapy in second-line gastroesophageal cancers Announced collaboration with Immunoscape for development of TCR-based therapies Published clinical data in Nature Communications and Oncogene demonstrating
Corporate Presentation

SEC Filings

Form Description Filing date View
10-K

Annual report which provides a comprehensive overview of the company for the past year

 View HTML
0001564590-22-011026.pdf
0001564590-22-011026.rtf
0001564590-22-011026.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
10-K

Annual report which provides a comprehensive overview of the company for the past year

 View HTML
0000950170-23-009762.pdf
0000950170-23-009762.rtf
0000950170-23-009762.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
10-K

Annual report which provides a comprehensive overview of the company for the past year

 View HTML
0000950170-24-034672.pdf
0000950170-24-034672.rtf
0000950170-24-034672.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
10-Q

Quarterly report which provides a continuing view of a company's financial position

 View HTML
0001564590-21-058700.pdf
0001564590-21-058700.rtf
0001564590-21-058700.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA

Data provided by Kaleidoscope.